With interest rates stabilizing in mid-2026, investors are focusing on Dividend Kings and Aristocrats known for decades of consecutive dividend increases. Johnson & Johnson, Coca-Cola, and McDonald's stand out for their strong Q1 earnings, reasonable valuations, and consistent dividend growth. JNJ raised its dividend for the 64th year with solid revenue growth driven by oncology products. KO reported a 12% revenue increase and raised guidance amid strong global sales. MCD, trading below its 200-day average, showed renewed sales momentum and a 5% dividend raise. These stocks offer reliable income and growth potential as the market environment steadies.
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supporte...
The SNPD ETF focuses on companies with long histories of increasing dividends, such as Johnson & Johnson, Coca-Cola, Procter & Gamble, PepsiCo, and Lowe's. These companies have strong free cash flow coverage supporting their payouts, making SNPD's di...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
